{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:30:05Z","timestamp":1789122605836,"version":"build-2803163510"},"reference-count":171,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007219","name":"Shanghai Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["23ZR1461000"],"award-info":[{"award-number":["23ZR1461000"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82474121"],"award-info":[{"award-number":["82474121"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174025"],"award-info":[{"award-number":["82174025"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ejmech.2025.118114","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T14:54:21Z","timestamp":1756565661000},"page":"118114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Pyrrolobenzodiazepine dimers for chemotherapy and antibody-drug conjugate applications"],"prefix":"10.1016","volume":"300","author":[{"given":"Xiumian","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0869-8314","authenticated-orcid":false,"given":"Changwu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118114_bib1","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1021\/ja00952a050","article-title":"Isolation and characterization of anthramycin, a new antitumor antibiotic","volume":"87","author":"Leimgruber","year":"1965","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118114_bib2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.7164\/antibiotics.25.437","article-title":"Studies on tomaymycin, a new antibiotic. I. Isolation and properties of tomaymycin","volume":"25","author":"Arima","year":"1972","journal-title":"J. Antibiot."},{"key":"10.1016\/j.ejmech.2025.118114_bib3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.7164\/antibiotics.30.340","article-title":"Structure and synthesis of neothramycin","volume":"30","author":"Miyamoto","year":"1977","journal-title":"J. Antibiot."},{"key":"10.1016\/j.ejmech.2025.118114_bib4","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1021\/bi00354a009","article-title":"DNA sequence specificity of the pyrrolo[1,4]benzodiazepine antitumor antibiotics. Methidiumpropyl-EDTA-iron(II) footprinting analysis of DNA binding sites for anthramycin and related drugs","volume":"25","author":"Hertzberg","year":"1986","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.118114_bib5","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1021\/tx00005a002","article-title":"Pyrrolo[1,4]benzodiazepine antitumor antibiotics: relationship of DNA alkylation and sequence specificity to the biological activity of natural and synthetic compounds","volume":"1","author":"Hurley","year":"1988","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118114_bib6","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/anie.201510610","article-title":"From anthramycin to pyrrolobenzodiazepine (PBD)-containing antibody-drug conjugates (ADCs)","volume":"56","author":"Mantaj","year":"2017","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.ejmech.2025.118114_bib7","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1158\/1538-7445.AM2018-736","article-title":"Abstract 736: pyridinobenzodiazepines (PDDs): a new class of sequence-selective DNA mono-alkylating ADC payloads with low hydrophobicity","volume":"78","author":"Veillard","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118114_bib8","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1021\/jm00045a019","article-title":"Comparison of a DSB-120 DNA interstrand cross-linked adduct with the corresponding bis-tomaymycin adduct: an example of a successful template-directed approach to drug design based upon the monoalkylating compound tomaymycin","volume":"37","author":"Mountzouris","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib9","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1021\/cr100120f","article-title":"Synthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines (PBDs)","volume":"111","author":"Antonow","year":"2011","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2025.118114_bib10","doi-asserted-by":"crossref","first-page":"19376","DOI":"10.1021\/ja205395r","article-title":"Observation of a single-stranded DNA\/pyrrolobenzodiazepine adduct","volume":"133","author":"Rahman","year":"2011","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118114_bib11","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/14712598.2020.1776255","article-title":"Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy","volume":"21","author":"Hartley","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ejmech.2025.118114_bib12","doi-asserted-by":"crossref","first-page":"618081","DOI":"10.3389\/fimmu.2021.618081","article-title":"An antibody-drug conjugate that selectively targets human monocyte progenitors for anti-cancer therapy","volume":"12","author":"Izumi","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118114_bib13","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.1016\/S0040-4039(00)80691-7","article-title":"Synthesis and dna crosslinking ability of a dimeric anthramycin analog","volume":"29","author":"Farmer","year":"1988","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2025.118114_bib14","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/S0960-894X(03)00436-0","article-title":"Synthesis of the first examples of A-C8\/C-C2 amide-linked pyrrolo[2,1-c][1,4]benzodiazepine dimers","volume":"13","author":"Gregson","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118114_bib15","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.1016\/j.tetlet.2008.04.006","article-title":"Synthesis of C8\u2013C8\/C2\u2013C8-linked triazolo pyrrolobenzodiazepine dimers by employing \u2018click\u2019 chemistry and their DNA-binding affinity","volume":"49","author":"Kamal","year":"2008","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2025.118114_bib16","first-page":"225","article-title":"Design, synthesis and in vitro cytotoxicity studies of novel pyrrolo[2,1-c][1,4]benzodiazepine (PBD)-polyamide conjugates and 2,2\u2032-PBD dimers","volume":"15","author":"Reddy","year":"2000","journal-title":"Anti Cancer Drug Des."},{"key":"10.1016\/j.ejmech.2025.118114_bib17","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1021\/ja00038a089","article-title":"Rational design of a highly efficient irreversible DNA interstrand cross-linking agent based on the pyrrolobenzodiazepine ring system","volume":"114","author":"Bose","year":"1992","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118114_bib18","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1039\/c39920001518","article-title":"Effect of linker length on DNA-binding affinity, cross-linking efficiency and cytotoxicity of C8-linked pyrrolobenzodiazepine dimers","author":"Bose","year":"1992","journal-title":"Journal of the Chemical Society, Chem. Commun."},{"key":"10.1016\/j.ejmech.2025.118114_bib19","first-page":"431","article-title":"Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120, cancer chemother","volume":"38","author":"Walton","year":"1996","journal-title":"Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118114_bib20","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.7164\/antibiotics.43.1286","article-title":"Evaluation of the electrophilicity of DNA-binding pyrrolo[2,1-c][1,4]benzodiazepines by HPLC","volume":"43","author":"Morris","year":"1990","journal-title":"J. Antibiot."},{"key":"10.1016\/j.ejmech.2025.118114_bib21","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1021\/jm001064n","article-title":"Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity","volume":"44","author":"Gregson","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib22","doi-asserted-by":"crossref","first-page":"6700","DOI":"10.1158\/0008-5472.CAN-03-2942","article-title":"SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations","volume":"64","author":"Alley","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118114_bib23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jchromb.2006.04.031","article-title":"LC-MS\/MS assay and dog pharmacokinetics of the dimeric pyrrolobenzodiazepine SJG-136 (NSC 694501)","volume":"840","author":"Buhrow","year":"2006","journal-title":"J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci."},{"key":"10.1016\/j.ejmech.2025.118114_bib24","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.1158\/0008-5472.CAN-03-2941","article-title":"SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity","volume":"64","author":"Hartley","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118114_bib25","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1158\/1078-0432.CCR-08-1315","article-title":"Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors","volume":"15","author":"Hochhauser","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118114_bib26","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s00280-009-1088-4","article-title":"A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors","volume":"65","author":"Janjigian","year":"2010","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118114_bib27","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1158\/1078-0432.CCR-10-2056","article-title":"Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors","volume":"17","author":"Puzanov","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118114_bib28","doi-asserted-by":"crossref","first-page":"6849","DOI":"10.1158\/0008-5472.CAN-10-0790","article-title":"SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity","volume":"70","author":"Hartley","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118114_bib29","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1158\/1535-7163.MCT-16-0233","article-title":"ADCT-301, a pyrrolobenzodiazepine (PBD) dimer\u2013containing antibody\u2013drug conjugate (ADC) targeting CD25-expressing hematological malignancies","volume":"15","author":"Flynn","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118114_bib30","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","volume":"131","author":"Zammarchi","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118114_bib31","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1158\/0008-5472.CAN-16-2854","article-title":"Antibody\u2013drug conjugates bearing pyrrolobenzodiazepine or tubulysin payloads are immunomodulatory and synergize with multiple immunotherapies","volume":"77","author":"Rios-Doria","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118114_bib32","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1124\/dmd.116.073031","article-title":"Antibody drug conjugates differentiate uptake and DNA alkylation of pyrrolobenzodiazepines in tumors from organs of xenograft mice","volume":"44","author":"Ma","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2025.118114_bib33","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1158\/1535-7163.MCT-16-0184","article-title":"A new class of antibody\u2013drug conjugates with potent DNA alkylating activity","volume":"15","author":"Miller","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118114_bib34","doi-asserted-by":"crossref","first-page":"114047","DOI":"10.1016\/j.biopha.2022.114047","article-title":"Antibody drug conjugates, targeting cancer-expressed EGFR, exhibit potent and specific antitumor activity","volume":"157","author":"Ho","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118114_bib35","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1021\/jm030897l","article-title":"Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8\/C8' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers","volume":"47","author":"Gregson","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib36","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s10637-011-9647-z","article-title":"DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057","volume":"30","author":"Hartley","year":"2011","journal-title":"Invest. New Drugs."},{"key":"10.1016\/j.ejmech.2025.118114_bib37","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1158\/1078-0432.CCR-18-1300","article-title":"SLC46A3 as a potential predictive biomarker for antibody\u2013drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads","volume":"24","author":"Kinneer","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118114_bib38","doi-asserted-by":"crossref","first-page":"13913","DOI":"10.1021\/acs.jmedchem.0c01385","article-title":"Design, synthesis, and structure\u2013activity relationships of novel tetrahydroisoquinolino benzodiazepine dimer antitumor agents and their application in antibody\u2013drug conjugates","volume":"63","author":"Chowdari","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib39","doi-asserted-by":"crossref","first-page":"9603","DOI":"10.1021\/acs.jmedchem.0c00691","article-title":"Systematic variation of pyrrolobenzodiazepine (PBD)-dimer payload physicochemical properties impacts efficacy and tolerability of the corresponding antibody\u2013drug conjugates","volume":"63","author":"Staben","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib40","series-title":"NOVEL CYTOTOXIC AGENTS FOR CONJUGATION OF DRUGS TO CELL BINDING MOLECULE","first-page":"1","author":"Zhao","year":"2018"},{"key":"10.1016\/j.ejmech.2025.118114_bib41","series-title":"Unsymmetrical pyrrolobenzodiazepine-dimers for Treatment of Proliferative Diseases","first-page":"74","author":"Howard","year":"2010"},{"key":"10.1016\/j.ejmech.2025.118114_bib42","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1016\/j.tetlet.2015.05.116","article-title":"Synthesis of a C2-aryl-pyrrolo[2,1-c][1,4]benzodiazepine monomer enabling the convergent construction of symmetrical and non-symmetrical dimeric analogs","volume":"56","author":"Kolakowski","year":"2015","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2025.118114_bib43","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","article-title":"SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML","volume":"122","author":"Kung Sutherland","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118114_bib44","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","article-title":"Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models","volume":"76","author":"Li","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118114_bib45","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1021\/bc400217g","article-title":"A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology","volume":"24","author":"Jeffrey","year":"2013","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib46","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1158\/1535-7163.MCT-17-0742","article-title":"Characterization of SGN-CD123A, a potent CD123-directed antibody-drug conjugate for acute myeloid leukemia","volume":"17","author":"Li","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118114_bib47","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1158\/1535-7163.MCT-20-0149","article-title":"Targeting multiple egfr-expressing tumors with a highly potent tumor-selective antibody-drug conjugate","volume":"19","author":"Anderson","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118114_bib48","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1186\/s12885-021-08403-5","article-title":"ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition","volume":"21","author":"Anderson","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejmech.2025.118114_bib49","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/cncr.31912","article-title":"A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma","volume":"125","author":"Pal","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2025.118114_bib50","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood-2017-06-789800","article-title":"A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia","volume":"131","author":"Stein","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118114_bib51","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13045-019-0771-0","article-title":"CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A","volume":"12","author":"Stanchina","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118114_bib52","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1158\/1535-7163.MCT-17-0710","article-title":"Characterization of ABBV-221, a tumor-selective EGFR-targeting antibody drug conjugate","volume":"17","author":"Phillips","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118114_bib53","first-page":"1","article-title":"Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: safety, pharmacokinetics, and antitumor activity in advanced glioblastoma, neurooncol","volume":"5","author":"Carneiro","year":"2022","journal-title":"Adv"},{"key":"10.1016\/j.ejmech.2025.118114_bib54","series-title":"Pyrrolobenzodiazepines and Conjugates Thereof","first-page":"203","author":"Howard","year":"2014"},{"key":"10.1016\/j.ejmech.2025.118114_bib55","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1021\/acsmedchemlett.6b00062","article-title":"Design and synthesis of tesirine, a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload, ACS","volume":"7","author":"Tiberghien","year":"2016","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118114_bib56","series-title":"Pyrrolobenzodiazepine-anti-HER2 Antibody Conjugates","first-page":"1","author":"Van Berkel","year":"2014"},{"key":"10.1016\/j.ejmech.2025.118114_bib57","doi-asserted-by":"crossref","first-page":"10479","DOI":"10.1038\/s41598-018-28533-4","article-title":"Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine","volume":"8","author":"Hartley","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118114_bib58","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2025.118114_bib59","first-page":"1184","article-title":"Loncastuximab tesirine in relapsed\/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study","volume":"109","author":"Caimi","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2025.118114_bib60","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2352-3026(24)00345-4","article-title":"Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre single-arm, phase 2 trial","volume":"12","author":"Alderuccio","year":"2025","journal-title":"Lancet. Haematology."},{"key":"10.1016\/j.ejmech.2025.118114_bib61","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.3324\/haematol.2023.284197","article-title":"Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy","volume":"109","author":"Tarantelli","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2025.118114_bib62","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/bloodadvances.2019000767","article-title":"Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed\/refractory B-cell acute lymphoblastic leukemia","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejmech.2025.118114_bib63","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2025.118114_bib64","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2025.118114_bib65","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study","volume":"16","author":"Blackhall","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2025.118114_bib66","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1158\/1535-7163.MCT-21-0715","article-title":"Preclinical development of ADCT-601, a novel pyrrolobenzodiazepine dimer-based antibody\u2013drug conjugate targeting AXL-expressing cancers","volume":"21","author":"Zammarchi","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118114_bib67","doi-asserted-by":"crossref","first-page":"CT059","DOI":"10.1158\/1538-7445.AM2024-CT059","article-title":"Abstract CT059: phase 1b trial mipasetamab Uzoptirine (ADCT-601-102) dose escalation in patients with advanced bone and soft tissue sarcomas","volume":"84","author":"Van Tine","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118114_bib68","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2020.04.017","article-title":"SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: phase 1 study","volume":"145","author":"Morgensztern","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejmech.2025.118114_bib69","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.OVCASYMP18-NT-113","article-title":"Abstract NT-113: SC-003, an antibody-drug conjugate targeting dipeptidase 3, exhibits potent anti-tumor activity in patient-derived xenograft models of high grade serous ovarian cancer","volume":"25","author":"Wiedemeyer","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118114_bib70","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ygyno.2020.05.038","article-title":"Tamrintamab pamozirine (SC-003) in patients with platinum-resistant\/refractory ovarian cancer: findings of a phase 1 study","volume":"158","author":"Hamilton","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118114_bib71","doi-asserted-by":"crossref","first-page":"e000860","DOI":"10.1136\/jitc-2020-000860","article-title":"CD25-targeted antibody-drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity","volume":"8","author":"Zammarchi","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejmech.2025.118114_bib72","doi-asserted-by":"crossref","first-page":"106385","DOI":"10.1016\/j.leukres.2020.106385","article-title":"Camidanlumab tesirine, an antibody-drug conjugate, in relapsed\/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: a phase I study","volume":"95","author":"Goldberg","year":"2020","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ejmech.2025.118114_bib73","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s10637-022-01300-z","article-title":"CD25-targeted antibody-drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma","volume":"40","author":"Xu","year":"2022","journal-title":"Invest. New Drugs."},{"key":"10.1016\/j.ejmech.2025.118114_bib74","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00280-022-04486-4","article-title":"Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory hodgkin lymphoma and non-hodgkin lymphoma","volume":"91","author":"Toukam","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118114_bib75","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1158\/1535-7163.MCT-17-0982","article-title":"Antitumor activity of MEDI3726 (ADCT-401), a pyrrolobenzodiazepine antibody\u2013drug conjugate targeting PSMA, in preclinical models of prostate cancer","volume":"17","author":"Cho","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118114_bib76","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1158\/1078-0432.CCR-20-4528","article-title":"Phase I study of MEDI3726: a prostate-specific membrane antigen-targeted antibody\u2013drug conjugate, in patients with mCRPC after failure of abiraterone or enzalutamide","volume":"27","author":"de Bono","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118114_bib77","doi-asserted-by":"crossref","first-page":"11135","DOI":"10.1021\/acs.analchem.0c01187","article-title":"Multifaceted bioanalytical methods for the comprehensive pharmacokinetic and catabolic assessment of MEDI3726, an anti-prostate-specific membrane antigen pyrrolobenzodiazepine antibody\u2013drug conjugate","volume":"92","author":"Huang","year":"2020","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib78","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/S0959-8049(16)32662-4","article-title":"ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody\u2013drug conjugate (ADC) targeting low HER2-expressing solid cancers","volume":"69","author":"Zammarchi","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118114_bib79","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/1878-0261.12600","article-title":"TR1801-ADC: a highly potent cMet antibody-drug conjugate with high activity in patient-derived xenograft models of solid tumors","volume":"14","author":"Gymnopoulos","year":"2020","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118114_bib80","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/1535-7163.MCT-23-0506","article-title":"ADCT-602, a novel PBD dimer\u2013containing antibody\u2013drug conjugate for treating CD22-positive hematologic malignancies","volume":"23","author":"Zammarchi","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118114_bib81","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1182\/blood-2022-170730","article-title":"ADCT-602, a CD22 targeting antibody drug conjugate bound to PBD toxin in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia: a phase 1 trial","volume":"140","author":"Jain","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118114_bib82","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41375-018-0278-7","article-title":"Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells","volume":"33","author":"Kinneer","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.118114_bib83","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41375-020-0745-9","article-title":"A novel BCMA PBD-ADC with ATM\/ATR\/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma","volume":"34","author":"Xing","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.118114_bib84","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-136375","article-title":"Phase 1, first-in-human study of MEDI2228, a BCMA-targeted ADC in patients with relapsed\/refractory multiple myeloma","volume":"136","author":"Kumar","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118114_bib85","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1021\/acsmedchemlett.7b00436","article-title":"Design and synthesis of isoquinolidinobenzodiazepine dimers, a novel class of antibody-drug conjugate payload","volume":"9","author":"Smith","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118114_bib86","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ygyno.2021.08.014","article-title":"DHES0815A, a novel antibody-drug conjugate targeting HER2\/neu, is highly active against uterine serous carcinomas in vitro and in vivo","volume":"163","author":"Tymon-Rosario","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118114_bib87","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1016\/j.tetlet.2017.10.010","article-title":"An optimised synthesis of SG3376, a non-cleavable antibody-drug conjugate pyrrolobenzodiazepine drug-linker","volume":"58","author":"Tiberghien","year":"2017","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.ejmech.2025.118114_bib88","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.bmcl.2017.01.074","article-title":"Synthesis and in vitro evaluation of SG3227, a pyrrolobenzodiazepine dimer antibody-drug conjugate payload based on sibiromycin","volume":"27","author":"Kemp","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118114_bib89","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1158\/1535-7163.MCT-22-0145","article-title":"Efficacy, tolerability, and pharmacokinetic studies of antibody-drug conjugates containing a low-potency pyrrolobenzodiazepine dimer","volume":"21","author":"Gregson","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118114_bib90","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2174\/1568026619666190401112517","article-title":"Potentiation of PBD dimers by lipophilicity manipulation","volume":"19","author":"Cailleau","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib91","doi-asserted-by":"crossref","first-page":"104429","DOI":"10.1016\/j.yrtph.2019.104429","article-title":"An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates","volume":"107","author":"Saber","year":"2019","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118114_bib93","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ddtec.2018.10.004","article-title":"Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: is mechanism related to systemic toxicity?","volume":"30","author":"Jackson","year":"2018","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejmech.2025.118114_bib94","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1158\/1535-7163.MCT-17-1077","article-title":"IMGN779, a novel CD33-targeting antibody-drug conjugate with DNA-alkylating activity, exhibits potent antitumor activity in models of AML","volume":"17","author":"Kovtun","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118114_bib95","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2018-99-112891","article-title":"Maturing clinical profile of IMGN779, a next-generation CD33-targeting antibody-drug conjugate, in patients with relapsed or refractory acute myeloid leukemia","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118114_bib96","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3324\/haematol.2018.211011","article-title":"The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models","volume":"104","author":"Hicks","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2025.118114_bib97","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/acs.molpharmaceut.9b00675","article-title":"Antibody-drug conjugates with indolinobenzodiazepine dimer payloads: DNA-binding mechanism of indolinobenzodiazepine dimer catabolites in target cancer cells","volume":"17","author":"Singh","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2025.118114_bib98","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1158\/1535-7163.MCT-17-0940","article-title":"A DNA-interacting payload designed to eliminate cross-linking improves the therapeutic index of antibody-drug conjugates (ADCs)","volume":"17","author":"Miller","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118114_bib99","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/bloodadvances.2018017517","article-title":"A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells","volume":"2","author":"Kovtun","year":"2018","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejmech.2025.118114_bib100","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","article-title":"Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study","volume":"25","author":"Daver","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2025.118114_bib101","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1158\/1535-7163.MCT-19-1102","article-title":"Preclinical antitumor activity and biodistribution of a novel anti-gcc antibody-drug conjugate in patient-derived xenografts","volume":"19","author":"Abu-Yousif","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118114_bib102","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1208\/s12248-022-00756-4","article-title":"Pharmacokinetics and pharmacodynamics of TAK-164 antibody drug conjugate coadministered with unconjugated antibody","volume":"24","author":"Menezes","year":"2022","journal-title":"AAPS J."},{"key":"10.1016\/j.ejmech.2025.118114_bib103","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/1535-7163.MCT-21-0693","article-title":"Comparison of pyrrolobenzodiazepine dimer bis-imine versus mono-imine: DNA interstrand cross-linking, cytotoxicity, antibody-drug conjugate efficacy and toxicity","volume":"22","author":"Tiberghien","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118114_bib104","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41467-023-44533-z","article-title":"The HER2-directed antibody-drug conjugate DHES0815A in advanced and\/or metastatic breast cancer: preclinical characterization and phase 1 trial results","volume":"15","author":"Lewis","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118114_bib105","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1158\/1535-7163.MCT-16-0641","article-title":"Modulating therapeutic activity and toxicity of pyrrolobenzodiazepine antibody-drug conjugates with self-immolative disulfide linkers","volume":"16","author":"Pillow","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118114_bib106","series-title":"Antibody-Pyrrolobenzodiazepine Deprivative Conjugate","first-page":"1","author":"Toda","year":"2022"},{"key":"10.1016\/j.ejmech.2025.118114_bib108","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ejmech.2019.06.044","article-title":"Synthesis and evaluation of pyrrolobenzodiazepine dimer antibody-drug conjugates with dual beta-glucuronide and dipeptide triggers","volume":"179","author":"Gregson","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib109","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2024-192979","article-title":"Safety and efficacy in patients with advanced lymphomas from a global phase 1a\/1b, first-in-human study of CS5001, a novel anti-ROR1 ADC","volume":"144","author":"Song","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.118114_bib110","first-page":"3023","article-title":"A phase 1a\/b, multi-regional, first-in-human study of CS5001, a novel anti-ROR1 ADC, in patients with advanced solid tumors and lymphomas","volume":"42","author":"Lemech","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118114_bib111","series-title":"Antibody-Drug Conjugates with Masked PBD Dimers","author":"Popal","year":"2024"},{"key":"10.1016\/j.ejmech.2025.118114_bib112","doi-asserted-by":"crossref","first-page":"126987","DOI":"10.1016\/j.bmcl.2020.126987","article-title":"Design and synthesis of a folate-receptor targeted diazepine-ring-opened pyrrolobenzodiazepine prodrug conjugate","volume":"30","author":"Vlahov","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118114_bib113","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1021\/acs.bioconjchem.7b00476","article-title":"Latent warheads for targeted cancer therapy: design and synthesis of pro-pyrrolobenzodiazepines and conjugates","volume":"28","author":"Vlahov","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib114","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1016\/j.bmcl.2017.10.023","article-title":"Design, synthesis, and biological evaluation of pyrrolobenzodiazepine-containing hypoxia-activated prodrugs","volume":"27","author":"Dragovich","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118114_bib115","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1021\/jm050956q","article-title":"Design, synthesis, and biological evaluation of pyrrolo[2,1-c][1,4]benzodiazepine and indole conjugates as anticancer agents","volume":"49","author":"Wang","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib116","doi-asserted-by":"crossref","first-page":"12223","DOI":"10.1021\/bi901655t","article-title":"Solution structure of a covalently bound pyrrolo[2,1-c][1,4]benzodiazepine-benzimidazole hybrid to a 10mer DNA duplex","volume":"48","author":"Rettig","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.118114_bib117","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejmech.2015.12.039","article-title":"Design and synthesis of pyrrolobenzodiazepine-gallic hybrid agents as p53-dependent and -independent apoptogenic signaling in melanoma cells","volume":"109","author":"Chou","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib118","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10565-012-9238-6","article-title":"DC-81-enediyne induces apoptosis of human melanoma A375 cells: involvement of the ROS, p38 MAPK, and AP-1 signaling pathways","volume":"29","author":"Chen","year":"2013","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.ejmech.2025.118114_bib119","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.1016\/j.bmc.2016.09.068","article-title":"Analogues of DNA minor groove cross-linking agents incorporating aminoCBI, an amino derivative of the duocarmycins: synthesis, cytotoxicity, and potential as payloads for antibody-drug conjugates","volume":"24","author":"Giddens","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib120","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3324\/haematol.2019.238584","article-title":"Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-kappaB activity and synergise with bortezomib and ibrutinib in hematological cancers","volume":"106","author":"Lewis","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2025.118114_bib121","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1021\/jm051199z","article-title":"Design, synthesis, and biophysical and biological evaluation of a series of pyrrolobenzodiazepine-poly(N-methylpyrrole) conjugates","volume":"49","author":"Wells","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib122","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1158\/1535-7163.MCT-07-0475","article-title":"Inhibition of DNA binding of the NF-Y transcription factor by the pyrrolobenzodiazepine-polyamide conjugate GWL-78","volume":"7","author":"Kotecha","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118114_bib123","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.bmc.2008.12.036","article-title":"Synthesis and antitumor activity of novel enediyne-linked pyrrolo[2,1-c][1,4]benzodiazepine hybrids","volume":"17","author":"Hu","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib124","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1021\/jm301882a","article-title":"GC-targeted C8-linked pyrrolobenzodiazepine-biaryl conjugates with femtomolar in vitro cytotoxicity and in vivo antitumor activity in mouse models","volume":"56","author":"Rahman","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib125","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1021\/jm020526p","article-title":"Unsymmetrical DNA cross-linking agents: combination of the CBI and PBD pharmacophores","volume":"46","author":"Tercel","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib126","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.bmcl.2019.07.031","article-title":"Design, synthesis and evaluation of novel, potent DNA alkylating agents and their antibody-drug conjugates (ADCs)","volume":"29","author":"Reid","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118114_bib127","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1021\/acsmedchemlett.0c00578","article-title":"DNA-model-based design and execution of some fused benzodiazepine hybrid payloads for antibody-drug conjugate modality","volume":"12","author":"Sivaprakasam","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118114_bib128","doi-asserted-by":"crossref","first-page":"128876","DOI":"10.1016\/j.bmcl.2022.128876","article-title":"Discovery of novel polyamide-pyrrolobenzodiazepine hybrids for antibody-drug conjugates","volume":"72","author":"Thomas","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118114_bib129","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3390\/cancers12041029","article-title":"A novel antibody-drug conjugate (ADC) delivering a DNA mono-alkylating payload to chondroitin sulfate proteoglycan (CSPG4)-expressing melanoma","volume":"12","author":"Hoffmann","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2025.118114_bib130","first-page":"741","article-title":"DNA sequence-selective G-A cross-linking ADC payloads for use in solid tumour therapies, Commun","volume":"5","author":"Procopiou","year":"2022","journal-title":"Biol"},{"key":"10.1016\/j.ejmech.2025.118114_bib131","doi-asserted-by":"crossref","first-page":"11679","DOI":"10.1021\/acs.jmedchem.2c00471","article-title":"Design, synthesis, and bioevaluation of a novel hybrid molecular pyrrolobenzodiazepine-anthracenecarboxyimide as a payload for antibody-drug conjugate","volume":"65","author":"Lai","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib132","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1158\/1535-7163.MCT-23-0622","article-title":"Development of a novel DNA mono-alkylator platform for antibody-drug conjugates","volume":"23","author":"Thomas","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118114_bib133","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/bc900315y","article-title":"Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates","volume":"21","author":"Erickson","year":"2010","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib134","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \"biological missile\" for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduction Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.118114_bib135","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0169-409X(02)00179-5","article-title":"Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities","volume":"55","author":"Saito","year":"2003","journal-title":"Adv. Drug Delivery Rev."},{"key":"10.1016\/j.ejmech.2025.118114_bib136","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1021\/bc100480a","article-title":"Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage","volume":"22","author":"Kellogg","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib137","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1016\/j.bmcl.2014.10.021","article-title":"Antibody-drug conjugates-A new wave of cancer drugs","volume":"24","author":"Bouchard","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118114_bib138","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2025.118114_bib139","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2025.118114_bib140","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1002\/pmic.201000196","article-title":"The proteome of lysosomes","volume":"10","author":"Schr\u00f6der","year":"2010","journal-title":"Proteomics"},{"key":"10.1016\/j.ejmech.2025.118114_bib141","doi-asserted-by":"crossref","DOI":"10.3390\/ph14050442","article-title":"The chemistry behind ADCs","volume":"14","author":"Kostova","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.118114_bib142","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1021\/bc0600214","article-title":"Development and properties of \u03b2-glucuronide linkers for monoclonal antibody-drug conjugates","volume":"17","author":"Jeffrey","year":"2006","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib143","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.687926","article-title":"Linker design impacts antibody-drug conjugate pharmacokinetics and efficacy via modulating the stability and payload release efficiency","volume":"12","author":"Su","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118114_bib144","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bmcl.2005.09.081","article-title":"Dipeptide-based highly potent doxorubicin antibody conjugates","volume":"16","author":"Jeffrey","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118114_bib145","doi-asserted-by":"crossref","DOI":"10.3390\/antib6040020","article-title":"Pyrrolobenzodiazepine antibody-drug conjugates designed for stable thiol conjugation","volume":"6","author":"Christie","year":"2017","journal-title":"Antibodies"},{"key":"10.1016\/j.ejmech.2025.118114_bib146","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1039\/C6SC01831A","article-title":"Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates","volume":"8","author":"Pillow","year":"2017","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2025.118114_bib147","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1158\/1535-7163.MCT-16-0641","article-title":"Modulating therapeutic activity and toxicity of pyrrolobenzodiazepine antibody-drug conjugates with self-immolative disulfide linkers","volume":"16","author":"Pillow","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118114_bib148","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1021\/acsmedchemlett.9b00254","article-title":"Synthesis of highly potent N-10 amino-linked DNA-alkylating indolinobenzodiazepine antibody-drug conjugates (ADCs)","volume":"10","author":"Archer","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118114_bib149","doi-asserted-by":"crossref","DOI":"10.3390\/antib10020020","article-title":"Clinical pharmacology of antibody-drug conjugates","volume":"10","author":"Mahmood","year":"2021","journal-title":"Antibodies"},{"key":"10.1016\/j.ejmech.2025.118114_bib150","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.ejmech.2025.118114_bib151","doi-asserted-by":"crossref","first-page":"15114","DOI":"10.1021\/jacs.8b10490","article-title":"Single-site labeling of native proteins enabled by a chemoselective and site-selective chemical technology","volume":"140","author":"Adusumalli","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118114_bib152","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1021\/jacs.7b12874","article-title":"Chemo-and regioselective lysine modification on native proteins","volume":"140","author":"Matos","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.118114_bib153","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/nbt.2968","article-title":"Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates","volume":"32","author":"Lyon","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2025.118114_bib154","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1021\/bc500148x","article-title":"Bridging disulfides for stable and defined antibody drug conjugates","volume":"25","author":"Badescu","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib155","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1002\/cmdc.201600372","article-title":"Introducing glycolinkers for the functionalization of cytotoxic drugs and applications in antibody-drug conjugation chemistry","volume":"11","author":"Ekholm","year":"2016","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118114_bib156","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/978-1-4939-9654-4_10","article-title":"Site-specific bioconjugation using SMARTag technology: a practical and effective chemoenzymatic approach to generate antibody-drug conjugates","volume":"2033","author":"Liu","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.118114_bib157","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1039\/C7OB01027C","article-title":"Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency","volume":"15","author":"Anami","year":"2017","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2025.118114_bib158","first-page":"434","article-title":"DNA damage repair system and antineoplastic agents in lung cancer","volume":"25","author":"Zhang","year":"2022","journal-title":"Zhong guo fei ai za zhi = Chinese journal of lung cancer"},{"key":"10.1016\/j.ejmech.2025.118114_bib159","doi-asserted-by":"crossref","first-page":"7980","DOI":"10.1128\/MCB.20.21.7980-7990.2000","article-title":"Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells","volume":"20","author":"De Silva","year":"2000","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118114_bib160","doi-asserted-by":"crossref","first-page":"6693","DOI":"10.1158\/0008-5472.CAN-03-2941","article-title":"SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity","volume":"64","author":"Hartley","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118114_bib161","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1080\/19420862.2018.1517565","article-title":"Preclinical pharmacokinetics and pharmacodynamics of DCLL9718A: an antibody-drug conjugate for the treatment of acute myeloid leukemia","volume":"10","author":"Leipold","year":"2018","journal-title":"mAbs"},{"key":"10.1016\/j.ejmech.2025.118114_bib162","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118114_bib163","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26196042","article-title":"Progress and future directions with peptide-drug conjugates for targeted cancer therapy","volume":"26","author":"Lindberg","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118114_bib164","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030713","article-title":"Mechanisms of ADC toxicity and strategies to increase ADC tolerability","volume":"15","author":"Nguyen","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118114_bib165","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-28533-4","article-title":"Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine","volume":"8","author":"Hartley","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118114_bib166","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1535-7163.MCT-20-0222","article-title":"The role of specific ATP-binding cassette transporters in the acquired resistance to pyrrolobenzodiazepine dimer-containing antibody-drug conjugates","volume":"19","author":"Corbett","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118114_bib167","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1158\/1078-0432.CCR-18-1300","article-title":"SLC46A3 as a potential predictive biomarker for antibody-drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads","volume":"24","author":"Kinneer","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118114_bib168","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","article-title":"Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity","volume":"77","author":"R\u00edos-Luci","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118114_bib169","doi-asserted-by":"crossref","first-page":"405","DOI":"10.32604\/or.2023.028310","article-title":"Targeting DNA repair for cancer treatment: lessons from PARP inhibitor trials","volume":"31","author":"Nambiar","year":"2023","journal-title":"Oncol. Res."},{"key":"10.1016\/j.ejmech.2025.118114_bib170","first-page":"1167","article-title":"Technology advancement in development of antibody drug conjugates","volume":"50","author":"Liu","year":"2023","journal-title":"Prog. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2025.118114_bib171","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1158\/1535-7163.MCT-16-0364","article-title":"Efficient payload delivery by a bispecific antibody-drug conjugate targeting HER2 and CD63","volume":"15","author":"de Goeij","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ejmech.2025.118114_bib172","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: making 1 + 1 > 2, Acta","volume":"14","author":"Gu","year":"2024","journal-title":"Der Pharm. Sin. B."},{"key":"10.1016\/j.ejmech.2025.118114_bib173","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1158\/1535-7163.MCT-20-1034","article-title":"Antibody-drug conjugate efficacy in neuroblastoma: role of payload, resistance mechanisms, target density, and antibody internalization","volume":"20","author":"Buongervino","year":"2021","journal-title":"Mol. Cancer Ther."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425008797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T19:40:01Z","timestamp":1772826001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425008797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":171,"alternative-id":["S0223523425008797"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118114","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pyrrolobenzodiazepine dimers for chemotherapy and antibody-drug conjugate applications","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118114"}}